BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

266 related articles for article (PubMed ID: 23824739)

  • 1. KEAP1-dependent synthetic lethality induced by AKT and TXNRD1 inhibitors in lung cancer.
    Dai B; Yoo SY; Bartholomeusz G; Graham RA; Majidi M; Yan S; Meng J; Ji L; Coombes K; Minna JD; Fang B; Roth JA
    Cancer Res; 2013 Sep; 73(17):5532-43. PubMed ID: 23824739
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Thioredoxin reductase-1 levels are associated with NRF2 pathway activation and tumor recurrence in non-small cell lung cancer.
    Delgobo M; Gonçalves RM; Delazeri MA; Falchetti M; Zandoná A; Nascimento das Neves R; Almeida K; Fagundes AC; Gelain DP; Fracasso JI; Macêdo GB; Priori L; Bassani N; Bishop AJR; Forcelini CM; Moreira JCF; Zanotto-Filho A
    Free Radic Biol Med; 2021 Dec; 177():58-71. PubMed ID: 34673143
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Auranofin-mediated inhibition of PI3K/AKT/mTOR axis and anticancer activity in non-small cell lung cancer cells.
    Li H; Hu J; Wu S; Wang L; Cao X; Zhang X; Dai B; Cao M; Shao R; Zhang R; Majidi M; Ji L; Heymach JV; Wang M; Pan S; Minna J; Mehran RJ; Swisher SG; Roth JA; Fang B
    Oncotarget; 2016 Jan; 7(3):3548-58. PubMed ID: 26657290
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Vorinostat synergizes with EGFR inhibitors in NSCLC cells by increasing ROS via up-regulation of the major mitochondrial porin VDAC1 and modulation of the c-Myc-NRF2-KEAP1 pathway.
    Leone A; Roca MS; Ciardiello C; Terranova-Barberio M; Vitagliano C; Ciliberto G; Mancini R; Di Gennaro E; Bruzzese F; Budillon A
    Free Radic Biol Med; 2015 Dec; 89():287-99. PubMed ID: 26409771
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibition of Thioredoxin/Thioredoxin Reductase Induces Synthetic Lethality in Lung Cancers with Compromised Glutathione Homeostasis.
    Yan X; Zhang X; Wang L; Zhang R; Pu X; Wu S; Li L; Tong P; Wang J; Meng QH; Jensen VB; Girard L; Minna JD; Roth JA; Swisher SG; Heymach JV; Fang B
    Cancer Res; 2019 Jan; 79(1):125-132. PubMed ID: 30401714
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibition of TXNRD or SOD1 overcomes NRF2-mediated resistance to β-lapachone.
    Torrente L; Prieto-Farigua N; Falzone A; Elkins CM; Boothman DA; Haura EB; DeNicola GM
    Redox Biol; 2020 Feb; 30():101440. PubMed ID: 32007910
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Induction of Oxidative Stress Through Inhibition of Thioredoxin Reductase 1 Is an Effective Therapeutic Approach for Hepatocellular Carcinoma.
    Lee D; Xu IM; Chiu DK; Leibold J; Tse AP; Bao MH; Yuen VW; Chan CY; Lai RK; Chin DW; Chan DF; Cheung TT; Chok SH; Wong CM; Lowe SW; Ng IO; Wong CC
    Hepatology; 2019 Apr; 69(4):1768-1786. PubMed ID: 30561826
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Plumbagin reduction by thioredoxin reductase 1 possesses synergy effects with GLUT1 inhibitor on KEAP1-mutant NSCLC cells.
    Sun S; Zhang Y; Xu W; Yang R; Yang Y; Guo J; Ma Q; Ma K; Zhang J; Xu J
    Biomed Pharmacother; 2022 Feb; 146():112546. PubMed ID: 34954641
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Thioredoxin reductase 1 inhibitor shikonin promotes cell necroptosis via SecTRAPs generation and oxygen-coupled redox cycling.
    Zhang Y; Sun S; Xu W; Yang R; Yang Y; Guo J; Ma K; Xu J
    Free Radic Biol Med; 2022 Feb; 180():52-62. PubMed ID: 34973363
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The thioredoxin reductase inhibitor auranofin induces heme oxygenase-1 in lung epithelial cells via Nrf2-dependent mechanisms.
    Dunigan K; Li Q; Li R; Locy ML; Wall S; Tipple TE
    Am J Physiol Lung Cell Mol Physiol; 2018 Oct; 315(4):L545-L552. PubMed ID: 30024305
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Functional dissection of Nrf2-dependent phase II genes in vascular inflammation and endotoxic injury using Keap1 siRNA.
    Kim JH; Choi YK; Lee KS; Cho DH; Baek YY; Lee DK; Ha KS; Choe J; Won MH; Jeoung D; Lee H; Kwon YG; Kim YM
    Free Radic Biol Med; 2012 Aug; 53(3):629-40. PubMed ID: 22609006
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Omics-based identification of an NRF2-related auranofin resistance signature in cancer: Insights into drug repurposing.
    Falchetti M; Delgobo M; Zancanaro H; Almeida K; das Neves RN; Dos Santos B; Stefanes NM; Bishop A; Santos-Silva MC; Zanotto-Filho A
    Comput Biol Med; 2023 Jan; 152():106347. PubMed ID: 36493734
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Enhancement of auranofin-induced lung cancer cell apoptosis by selenocystine, a natural inhibitor of TrxR1 in vitro and in vivo.
    Fan C; Zheng W; Fu X; Li X; Wong YS; Chen T
    Cell Death Dis; 2014 Apr; 5(4):e1191. PubMed ID: 24763048
    [TBL] [Abstract][Full Text] [Related]  

  • 14. RNAi-mediated silencing of nuclear factor erythroid-2-related factor 2 gene expression in non-small cell lung cancer inhibits tumor growth and increases efficacy of chemotherapy.
    Singh A; Boldin-Adamsky S; Thimmulappa RK; Rath SK; Ashush H; Coulter J; Blackford A; Goodman SN; Bunz F; Watson WH; Gabrielson E; Feinstein E; Biswal S
    Cancer Res; 2008 Oct; 68(19):7975-84. PubMed ID: 18829555
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Regulatory role of KEAP1 and NRF2 in PPARγ expression and chemoresistance in human non-small-cell lung carcinoma cells.
    Zhan L; Zhang H; Zhang Q; Woods CG; Chen Y; Xue P; Dong J; Tokar EJ; Xu Y; Hou Y; Fu J; Yarborough K; Wang A; Qu W; Waalkes MP; Andersen ME; Pi J
    Free Radic Biol Med; 2012 Aug; 53(4):758-68. PubMed ID: 22684020
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combination treatment with MEK and AKT inhibitors is more effective than each drug alone in human non-small cell lung cancer in vitro and in vivo.
    Meng J; Dai B; Fang B; Bekele BN; Bornmann WG; Sun D; Peng Z; Herbst RS; Papadimitrakopoulou V; Minna JD; Peyton M; Roth JA
    PLoS One; 2010 Nov; 5(11):e14124. PubMed ID: 21124782
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Auranofin, a gold(I)-containing antirheumatic compound, activates Keap1/Nrf2 signaling via Rac1/iNOS signal and mitogen-activated protein kinase activation.
    Kim NH; Oh MK; Park HJ; Kim IS
    J Pharmacol Sci; 2010; 113(3):246-54. PubMed ID: 20647686
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Molecular mechanisms for the regulation of Nrf2-mediated cell proliferation in non-small-cell lung cancers.
    Yamadori T; Ishii Y; Homma S; Morishima Y; Kurishima K; Itoh K; Yamamoto M; Minami Y; Noguchi M; Hizawa N
    Oncogene; 2012 Nov; 31(45):4768-77. PubMed ID: 22249257
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dysfunctional KEAP1-NRF2 interaction in non-small-cell lung cancer.
    Singh A; Misra V; Thimmulappa RK; Lee H; Ames S; Hoque MO; Herman JG; Baylin SB; Sidransky D; Gabrielson E; Brock MV; Biswal S
    PLoS Med; 2006 Oct; 3(10):e420. PubMed ID: 17020408
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Atg7- and Keap1-dependent autophagy protects breast cancer cell lines against mitoquinone-induced oxidative stress.
    Gonzalez Y; Aryal B; Chehab L; Rao VA
    Oncotarget; 2014 Mar; 5(6):1526-37. PubMed ID: 24681637
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.